Cargando…
Phloretin in Benign Prostate Hyperplasia and Prostate Cancer: A Contemporary Systematic Review
Currently, medication for benign prostate hyperplasia (BPH) and prostate cancer (PCa) are mainly based on modulating the hormone and nervous systems. However, side effects often affect patients, and might decrease their commitment to continuing the medication and lower their quality of life. Some st...
Autores principales: | Yang, Che-Hsueh, Ou, Yen-Chuan, Lin, Chi-Chien, Lin, Yi-Sheng, Tung, Min-Che, Yu, Chia-Cheng, Lin, Jen-Tai, Wen, Chen-Yueh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322491/ https://www.ncbi.nlm.nih.gov/pubmed/35888117 http://dx.doi.org/10.3390/life12071029 |
Ejemplares similares
-
Phloretin Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by Regulating the Inflammatory Response, Oxidative Stress and Apoptosis
por: Hsu, Chao Yu, et al.
Publicado: (2021) -
Incidental Prostate Cancer from Prostate with Benign Biopsies: A Predictive and Survival Analysis from Cohort Study
por: Yang, Che Hsueh, et al.
Publicado: (2022) -
Contemporary review of the 532 nm laser for treatment of benign prostatic hyperplasia
por: Chughtai, Bilal, et al.
Publicado: (2015) -
Benign Prostatic Hyperplasia
Publicado: (2015) -
Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk
por: Hung, S-C, et al.
Publicado: (2013)